Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma

Inclusion Criteria: * Histologically confirmed Ewing's sarcoma * Normal organ and bone marrow function * Life expectancy of at least 16 weeks * Not pregnant or breastfeeding * Willing and able to comply with the protocol for the duration of the study * Presence of measurable disease Exclusion Criteria: * Involvement in the planning and/or conduct of ths study * Previous enrollment in the present study * Participation in another clinical study with an investigational product during the 21 days prior to first dose of study drug * Previous exposure to any PARP inhibitor * Receiving systemic chemotherapy or radiotherapy within 2 weeks of beginning study treatment * Receiving prohibited classes of inhibitors of CYP3A4 * Persistent clinically significant toxicities caused by previous cancer therapy * Known myelodysplastic syndrome or acute myeloid leukemia * Symptomatic, uncontrolled brain metastases * Major surgery within 14 days of starting study treatment * Considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disorder or active, uncontrolled infection * Unable to swallow orally administered medication or with gastrointestinal disorders likely to interfere with absorption of the study medication * Known to be serologically positive for HIV and receiving antiretroviral therapy * Known active Hepatitis B or C * Known hypersensitivity to olaparib or any of the excipients of the product * Uncontrolled seizures